JPMorgan doctor survey confirms long-term potential of Ingrezza | NBIX Message Board Posts

Neurocrine Biosciences, Inc.

  NBIX website

NBIX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  47761 of 47799  at  3/31/2021 12:39:51 PM  by

softballDad


JPMorgan doctor survey confirms long-term potential of Ingrezza

"JPMorgan doctor survey confirms long-term potential of Ingrezza
 
"JPMorgan analyst Anupam Rama says his survey of 25 U.S. physicians confirm the long-term potential of Neurocrine Biosciences' Ingrezza. There is "plenty of room" to continue to penetrate the tardive dyskinesia market and Neurocrine's Ingrezza market share is expected to grow, Rama tells investors in a research note. That said, near-term Ingrezza market dynamics due to the ongoing COVID-19 pandemic are still uncertain, says Rama. He keeps a Neutral rating on Neurocrine shares with a $124 price target."

https://thefly.com/landingPageNews.php?id=3275542&headline=NBIX-JPMorgan-doctor-survey-confirms-longterm-potential-of-Ingrezza


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 0
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board








Financial Market Data provided by
.
Loading...